ClinicalTrials.gg
CompletedNCT02808312Updated Jan 7, 2021Results posted

Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function

A Phase 1 interventional study of Cilofexor in Nonalcoholic Steatohepatitis (NASH) and Primary Sclerosing Cholangitis (PSC), sponsored by Gilead Sciences. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Gilead Sciences.

Enrollment
16th of 16
57 · median 161
Started
2016
with 5 others
Phase 1
3 of 16
none open now
Registered
7th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 16th largest by enrollment, is one of 6 that started in 2016, is one of 3 in phase 1, and was the 7th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

None of the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences as a file.
02

Study summary

The primary objective of this study is to evaluate the single-dose pharmacokinetics of cilofexor in adults with impaired hepatic function relative to matched, healthy controls with normal hepatic function.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH)
  • Primary Sclerosing Cholangitis (PSC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

Cohort 1:

  • Individuals with mildly impaired and normal hepatic function.
  • Individuals with mild hepatic impairment must have a score of 5-6 on the -Turcotte (CPT) classification at screening without evidence of worsening clinical and/or laboratory signs of hepatic impairment within 2 months prior or within the screening period.

Cohort 2:

  • Individuals with moderately impaired and normal hepatic function.
  • Individuals with moderate hepatic impairment must have a score of 7-9 on the CPT classification at screening without evidence of worsening clinical and/or laboratory signs of hepatic impairment within 2 months prior or within the screening period.

Cohort 3:

  • Individuals with severely impaired and normal hepatic function.
  • Individuals with severe hepatic impairment must have a score of 10-15 on the CPT classification at screening without evidence of worsening clinical and/or laboratory signs of hepatic impairment within 2 months prior or within the screening period.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Cohort 1: Mild Hepatic Impairment

    Participants with mild hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).

    Drug: Cilofexor

  • Experimental
    Cohort 1: Normal Hepatic Function

    Matched normal hepatic function participants to mild hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).

    Drug: Cilofexor

  • Experimental
    Cohort 2: Moderate Hepatic Impairment

    Participants with moderate hepatic impairment will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).

    Drug: Cilofexor

  • Experimental
    Cohort 2: Normal Hepatic Function

    Matched normal hepatic function participants to moderate hepatic impairment participants will receive a single oral dose of cilofexor 30 mg (3 x 10 mg tablets).

    Drug: Cilofexor

  • Experimental
    Cohort 3: Severe Hepatic Impairment

    Participants with severe hepatic impairment will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).

    Drug: Cilofexor

  • Experimental
    Cohort 3: Normal Hepatic Function

    Matched normal hepatic function participants to severe hepatic impairment participants will receive a single oral dose of cilofexor 10 mg (1 x 10 mg tablet).

    Drug: Cilofexor

Interventions

  • Tablet(s) administered orally in a fed state on Day 1

    Also known as: GS-9674

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic (PK) Parameter: AUClast of Cilofexor

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  2. PK Parameter: AUCinf of Cilofexor

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  3. PK Parameter: Cmax of Cilofexor

    Cmax is defined as the maximum concentration of drug.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  4. PK Parameter: %AUCexp of Cilofexor

    %AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  5. PK Parameter: Clast of Cilofexor

    Clast is defined as the last observable concentration of drug.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  6. PK Parameter: Tmax of Cilofexor

    Tmax is defined as the time (observed time point) of Cmax.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  7. PK Parameter: Tlast of Cilofexor

    Tlast is defined as the time (observed time point) of Clast.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  8. PK Parameter: λz of Cilofexor

    λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  9. PK Parameter: CL/F of Cilofexor

    CL/F is defined as the apparent oral clearance following administration of the drug.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  10. PK Parameter: Vz/F of Cilofexor

    Vz/F is defined as the apparent volume of distribution of the drug.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

  11. PK Parameter: t1/2 of Cilofexor

    t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

    Time frame: ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1

Secondary outcomes

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events

    Time frame: Day 1 up to Day 31

  2. Percentage of Participants Who Experienced Graded Laboratory Abnormalities

    A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose at any time postdose up to and including the date of last study drug dose plus 30 days. The most severe graded abnormality from all tests was counted for each participant.

    Time frame: Day 1 up to Day 31

  3. Pharmacodynamic (PD) Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for α-hydroxy-4-cholesten-3-one (C4)

    AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

    Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1

  4. PD Parameter: Mean Day 1/ Day -1 Ratio of Cmin for α-hydroxy-4-cholesten-3-one (C4)

    Cmin for C4 is defined as the minimum observed concentration of C4. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

    Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1

  5. PD Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for Fibroblast Growth Factor 19 (FGF19)

    AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

    Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1

  6. PD Parameter: Mean Day 1/ Day -1 Ratio of Cmax for Fibroblast Growth Factor 19 (FGF19)

    Cmax for FGF19 is defined as the maximum observed concentration of FGF19. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

    Time frame: 0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1

07

Results

Posted Sep 30, 2020

Participant flow

Participants were enrolled at study sites in the United States (US) and New Zealand. The first participant was screened on 13 July 2016. The last study visit occurred on 16 October 2018.

Participant flow — Overall Study
MilestoneCohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 & 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
Started1010171010
Completed1010161010
Not completed00100
Withdrew: Enrolled but never treated00100

Outcome measures

PrimaryPharmacokinetic (PK) Parameter: AUClast of Cilofexor

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
Pharmacokinetic (PK) Parameter: AUClast of Cilofexor
h*ng/mLCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
Pharmacokinetic (PK) Parameter: AUClast of Cilofexor5381.0 ± 2175.342972.6 ± 1230.498223.7 ± 7492.412756.7 ± 851.386534.3 ± 3791.05960.0 ± 352.71
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 1.7869 · 90% CI 1.2885 to 2.4781
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 2.4868 · 90% CI 1.6735 to 3.6954
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 6.3240 · 90% CI 4.3675 to 9.1569
PrimaryPK Parameter: AUCinf of Cilofexor

AUCinf is defined as the concentration of drug extrapolated to infinite time.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · h*ng/mL
PK Parameter: AUCinf of Cilofexor
h*ng/mLCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: AUCinf of Cilofexor5411.9 ± 2181.823024.3 ± 1224.028288.2 ± 7583.422805.6 ± 851.266719.4 ± 4056.73986.2 ± 354.93
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 1.7628 · 90% CI 1.2750 to 2.4374
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 2.4559 · 90% CI 1.6531 to 3.6486
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 6.2497 · 90% CI 4.2965 to 9.0910
PrimaryPK Parameter: Cmax of Cilofexor

Cmax is defined as the maximum concentration of drug.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Cmax of Cilofexor
ng/mLCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: Cmax of Cilofexor994.1 ± 533.38603.5 ± 275.33909.2 ± 477.20495.7 ± 199.45426.6 ± 136.40182.4 ± 86.67
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 1.5703 · 90% CI 1.0723 to 2.2995
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 1.7343 · 90% CI 1.2193 to 2.4667
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 2.5369 · 90% CI 1.7562 to 3.6648
PrimaryPK Parameter: %AUCexp of Cilofexor

%AUCexp is defined as the percentage of AUC extrapolated between AUClast and AUCinf.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · percentage of AUCexp
PK Parameter: %AUCexp of Cilofexor
percentage of AUCexpCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: %AUCexp of Cilofexor0.63 ± 0.2701.95 ± 1.6210.64 ± 0.1941.87 ± 1.6531.81 ± 1.8742.96 ± 1.962
PrimaryPK Parameter: Clast of Cilofexor

Clast is defined as the last observable concentration of drug.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · ng/mL
PK Parameter: Clast of Cilofexor
ng/mLCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: Clast of Cilofexor1.97 ± 1.0053.84 ± 2.1622.76 ± 3.3773.73 ± 2.3786.03 ± 8.0442.18 ± 1.387
PrimaryPK Parameter: Tmax of Cilofexor

Tmax is defined as the time (observed time point) of Cmax.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Median · hours
PK Parameter: Tmax of Cilofexor
hoursCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: Tmax of Cilofexor3.75 (2.50 to 5.00)3.00 (2.50 to 4.00)4.50 (2.50 to 10.00)3.75 (2.50 to 4.00)5.00 (5.00 to 6.00)4.00 (3.00 to 5.00)
PrimaryPK Parameter: Tlast of Cilofexor

Tlast is defined as the time (observed time point) of Clast.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Median · hours
PK Parameter: Tlast of Cilofexor
hoursCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: Tlast of Cilofexor64.80 (48.00 to 72.02)48.00 (24.00 to 72.00)72.00 (72.00 to 96.00)48.00 (24.00 to 72.00)96.00 (96.00 to 96.00)48.00 (24.00 to 48.00)
PrimaryPK Parameter: λz of Cilofexor

λz is defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · 1/hour
PK Parameter: λz of Cilofexor
1/hourCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: λz of Cilofexor0.070 ± 0.03770.099 ± 0.06610.051 ± 0.01520.100 ± 0.06550.045 ± 0.01170.099 ± 0.0659
PrimaryPK Parameter: CL/F of Cilofexor

CL/F is defined as the apparent oral clearance following administration of the drug.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · mL/h
PK Parameter: CL/F of Cilofexor
mL/hCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: CL/F of Cilofexor6621.5 ± 3219.5011324.4 ± 4184.325264.4 ± 2686.2611631.7 ± 3666.251963.1 ± 964.1911535.9 ± 4627.39
PrimaryPK Parameter: Vz/F of Cilofexor

Vz/F is defined as the apparent volume of distribution of the drug.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · mL
PK Parameter: Vz/F of Cilofexor
mLCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: Vz/F of Cilofexor97797.6 ± 18500.74148898.5 ± 81520.1999541.7 ± 31192.41153854.9 ± 83844.3741375.1 ± 11767.71160423.9 ± 92259.03
PrimaryPK Parameter: t1/2 of Cilofexor

t1/2 is defined as the estimate of the terminal elimination half-life of the drug.

Time frame:
≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16, 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Median · hours
PK Parameter: t1/2 of Cilofexor
hoursCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PK Parameter: t1/2 of Cilofexor11.45 (8.50 to 12.94)9.49 (4.78 to 11.67)13.53 (11.56 to 18.15)8.12 (4.90 to 15.02)15.90 (12.85 to 19.02)9.31 (5.15 to 11.61)
SecondaryPercentage of Participants Experiencing Treatment-Emergent Adverse Events
Time frame:
Day 1 up to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing Treatment-Emergent Adverse Events
percentage of participantsCohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 and 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
Percentage of Participants Experiencing Treatment-Emergent Adverse Events10.020.012.530.00
SecondaryPercentage of Participants Who Experienced Graded Laboratory Abnormalities

A treatment-emergent laboratory abnormality was defined as an increase of at least 1 toxicity grade from predose at any time postdose up to and including the date of last study drug dose plus 30 days. The most severe graded abnormality from all tests was counted for each participant.

Time frame:
Day 1 up to Day 31
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced Graded Laboratory Abnormalities
percentage of participantsCohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 and 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
Any Laboratory Abnormality90.0100.050.0100.060.0
Grade 3 or above Laboratory Abnormalities20.020.0040.00
SecondaryPharmacodynamic (PD) Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for α-hydroxy-4-cholesten-3-one (C4)

AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

Time frame:
0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · ratio
Pharmacodynamic (PD) Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for α-hydroxy-4-cholesten-3-one (C4)
ratioCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
Pharmacodynamic (PD) Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for α-hydroxy-4-cholesten-3-one (C4)0.706 ± 0.22730.817 ± 0.28360.716 ± 0.23700.681 ± 0.26141.063 ± 0.24690.978 ± 0.4155
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 0.8722 · 90% CI 0.6827 to 1.1144
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 1.0731 · 90% CI 0.8295 to 1.3883
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 1.1475 · 90% CI 0.8783 to 1.4992
SecondaryPD Parameter: Mean Day 1/ Day -1 Ratio of Cmin for α-hydroxy-4-cholesten-3-one (C4)

Cmin for C4 is defined as the minimum observed concentration of C4. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

Time frame:
0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · ratio
PD Parameter: Mean Day 1/ Day -1 Ratio of Cmin for α-hydroxy-4-cholesten-3-one (C4)
ratioCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PD Parameter: Mean Day 1/ Day -1 Ratio of Cmin for α-hydroxy-4-cholesten-3-one (C4)0.599 ± 0.32720.707 ± 0.28380.668 ± 0.23840.583 ± 0.16340.953 ± 0.20730.727 ± 0.2674
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 0.8188 · 90% CI 0.5837 to 1.1486
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 1.1323 · 90% CI 0.8772 to 1.4615
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 1.3563 · 90% CI 1.0468 to 1.7574
SecondaryPD Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for Fibroblast Growth Factor 19 (FGF19)

AUC2-12 is defined as area under the curve calculated by the trapezoidal rule for the time from 2 to 12 hours. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

Time frame:
0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · ratio
PD Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for Fibroblast Growth Factor 19 (FGF19)
ratioCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PD Parameter: Mean Day 1/ Day -1 Ratio of AUC2-12 for Fibroblast Growth Factor 19 (FGF19)3.031 ± 1.03762.840 ± 0.92543.730 ± 1.37682.848 ± 1.02501.582 ± 0.81822.179 ± 1.6972
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 1.0658 · 90% CI 0.8275 to 1.3726
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 1.2942 · 90% CI 0.9663 to 1.7334
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 0.8225 · 90% CI 0.5479 to 1.2347
SecondaryPD Parameter: Mean Day 1/ Day -1 Ratio of Cmax for Fibroblast Growth Factor 19 (FGF19)

Cmax for FGF19 is defined as the maximum observed concentration of FGF19. For PD assessments on Day -1, participants were administered a single oral dose of placebo-to-match cilofexor tablet on Day -1; the reported Time Frame is with respect to the placebo dosing.

Time frame:
0.5 hour predose, ≤ 5 minutes predose, and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, and 16 hours postdose on Day -1 and Day 1; 4.5 hours postdose on Day -1; 24, 48, 72, and 96 hours postdose on Day 1
Reported as:
Mean · ratio
PD Parameter: Mean Day 1/ Day -1 Ratio of Cmax for Fibroblast Growth Factor 19 (FGF19)
ratioCohort 1: Mild Hepatic ImpairmentCohort 1: Normal Hepatic FunctionCohort 2: Moderate Hepatic ImpairmentCohort 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
PD Parameter: Mean Day 1/ Day -1 Ratio of Cmax for Fibroblast Growth Factor 19 (FGF19)3.778 ± 1.49543.494 ± 1.44234.459 ± 1.98993.145 ± 1.44841.899 ± 1.16192.098 ± 1.1579
Statistical analysis
  • Cohort 1: Mild Hepatic Impairment vs Cohort 1: Normal Hepatic Function · Glsm ratio: 1.0806 · 90% CI 0.7910 to 1.4762
  • Cohort 2: Moderate Hepatic Impairment vs Cohort 2: Normal Hepatic Function · Glsm ratio: 1.3729 · 90% CI 0.9663 to 1.9506
  • Cohort 3: Severe Hepatic Impairment vs Cohort 3: Normal Hepatic Function · Glsm ratio: 0.9030 · 90% CI 0.6142 to 1.3275

Adverse events

Collected over Day 1 up to Day 31. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Mild Hepatic Impairment0/10 (0%)0/10 (0%)1/10 (10%)
Cohort 2: Moderate Hepatic Impairment0/10 (0%)1/10 (10%)1/10 (10%)
Cohort 1 and 2: Normal Hepatic Function0/16 (0%)0/16 (0%)2/16 (12.5%)
Cohort 3: Severe Hepatic Impairment0/10 (0%)1/10 (10%)2/10 (20%)
Cohort 3: Normal Hepatic Function0/10 (0%)0/10 (0%)0/10 (0%)
Most frequent serious events
Most frequent serious events
EventCohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 and 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
Gastrointestinal haemorrhageGastrointestinal disorders0/101/100/160/100/10
Upper gastrointestinal haemorrhageGastrointestinal disorders0/100/100/161/100/10
Most frequent other events
Most frequent other events
EventCohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 and 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic Function
DyspepsiaGastrointestinal disorders0/101/100/160/100/10
Skin abrasionInjury, poisoning and procedural complications0/100/100/161/100/10
ArthralgiaMusculoskeletal and connective tissue disorders0/100/100/161/100/10
HaematomaVascular disorders1/100/100/160/100/10
Back painMusculoskeletal and connective tissue disorders0/100/101/160/100/10
HeadacheNervous system disorders0/100/101/160/100/10

Baseline characteristics

The Safety Analysis Set included all participants who took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Cohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 & 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic FunctionTotal
Mean54 ± 10.157 ± 8.955 ± 7.654 ± 9.552 ± 8.454.45 ± 8.67
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 & 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic FunctionTotal
Female3253316
Male78117740
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 & 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic FunctionTotal
Hispanic or Latino4376525
Not Hispanic or Latino6794531
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 & 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic FunctionTotal
American Indian or Alaska Native000000
Asian101002
Native Hawaiian or Other Pacific Islander000000
Black or African American100113
White810159951
More than one race000000
Unknown or Not Reported000000
Region of Enrollment
Region of Enrollment(participants)Cohort 1: Mild Hepatic ImpairmentCohort 2: Moderate Hepatic ImpairmentCohort 1 & 2: Normal Hepatic FunctionCohort 3: Severe Hepatic ImpairmentCohort 3: Normal Hepatic FunctionTotal
New Zealand213118
United States89139948
08

Study locations

5 sites
  • Miami, Florida 33014, United States
  • Orlando, Florida 32809, United States
  • Knoxville, Tennessee 37920, United States
  • San Antonio, Texas 78215, United States
  • Auckland, 1640, New Zealand
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Oct 2018, 27 months.

Results were first posted in Sep 2020, 1 year 11 months after primary completion.

Of 104 industry-sponsored phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 27 months is above that.

Counting every sponsor, half of 125 studies reached it within 10 months; a quarter within 5 and three quarters within 21.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 17, 2016
First posted
Jun 21, 2016
StartActual
Jul 13, 2016
Primary completionActual
Oct 16, 2018
CompletionActual
Oct 16, 2018
Results first posted
Sep 30, 2020
Last update
Jan 7, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02808312
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 21, 2016
Start date
Jul 13, 2016
Primary completion
Oct 16, 2018
Completion
Oct 16, 2018
Results posted
Sep 30, 2020
Last update
Jan 7, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cilofexor

Start the discussion